Methylnaltrexone Ion Pair Formulation for Oral Laxation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current oral dosage forms of methylnaltrexone are ineffective in treating opioid-induced constipation due to poor bioavailability and absorption in the gastrointestinal tract, with enterically coated formulations failing to induce laxation and uncoated formulations showing inconsistent results.
Innovation Solution
Development of a pharmaceutical composition comprising methylnaltrexone in the form of a tablet with an ion pair formed between methylnaltrexone and an amphiphilic pharmaceutically acceptable excipient, such as sodium lauryl sulfate, which increases the drug's lipophilicity and absorption by forming an ion pair that dissolves rapidly in the stomach, enhancing local gastric and systemic effects for laxation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If enterically coated formulations of methylnaltrexone are used, then the drug is protected from stomach acid and released in the intestine, but the formulations fail to induce laxation and show poor bioavailability
Solution Approach 1:
The patent removes the enteric coating from methylnaltrexone tablets, extracting the protective function to allow direct dissolution in the stomach. This enables the drug to be released in the gastric environment where it can rapidly dissolve and achieve effective plasma concentrations for laxation, rather than being trapped in the intestine where it fails to produce the desired effect.
Solution Approach 2:
The patent changes the dissolution parameters of methylnaltrexone by formulating it as an immediate-release tablet without enteric coating. This parameter change allows the drug to dissolve rapidly in the acidic gastric environment, achieving peak plasma concentrations that are sufficient to induce laxation, whereas enterically coated formulations failed to achieve adequate dissolution and absorption.
2Speed
If uncoated formulations of methylnaltrexone are used, then the drug dissolves in the stomach, but absorption is inconsistent and bioavailability is poor
Solution Approach 1:
The patent optimizes the formulation parameters of uncoated methylnaltrexone tablets to enhance dissolution rate and absorption consistency. By adjusting excipient composition and tablet formulation, the drug achieves rapid and reliable dissolution in the stomach with consistent bioavailability, transforming the previously inconsistent absorption profile into a predictable and effective therapeutic response.
3Reliability
If high doses of methylnaltrexone are administered to achieve systemic effects, then laxation may be induced, but the risk of central nervous system effects and opioid withdrawal symptoms increases
Solution Approach 1:
The patent creates a local concentration gradient of methylnaltrexone in the gastrointestinal tract by using immediate-release formulation that dissolves rapidly in the stomach. This produces high local concentrations at the site of action (peripheral opioid receptors in the GI tract) while limiting systemic absorption and central nervous system exposure, thereby achieving reliable laxation efficacy without increasing the risk of CNS side effects or opioid withdrawal symptoms.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition achieves effective laxation at peak plasma levels lower than those required for subcutaneous injection, demonstrating improved bioavailability and efficacy in treating opioid-induced constipation by enhancing absorption and local action in the gastrointestinal tract.
Implementation Method 1
a pharmaceutical composition comprising methylnaltrexone in the form of a tablet with an ion pair formed between methylnaltrexone and an amphiphilic pharmaceutically acceptable excipient, such as sodium lauryl sulfate, which increases the drug's lipophilicity and absorption
Implementation Method 2
which increases the drug's lipophilicity and absorption by forming an ion pair that dissolves rapidly in the stomach
Implementation Method 3
forming an ion pair that dissolves rapidly in the stomach, enhancing local gastric and systemic effects for laxation
Data Source
Figure 1~2
Figure 3
Figure 4A
AI summary
The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.